GlassScriptPhysician profile
Mary A Finke
NPI 1831133560
$619.94
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $84.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168.71 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $77.43 | 2019 | |
| Mylan Pharmaceuticals INC. | $65.99 | 2019 | |
| Pfizer INC. | $58.72 | 2019-2020 | |
| Therapeuticsmd, INC. | $52.55 | 2019-2020 | |
| Roche Diagnostics Corporation | $43.37 | 2019-2020 | |
| Duchesnay USA Incorporated | $38.15 | 2019 | |
| Avion Pharmaceuticals | $27.88 | 2019-2020 | |
| Daiichi Sankyo INC. | $21.71 | 2019 | |
| Lupin INC. | $18.99 | 2019 | |
| Millicent US INC | $18.08 | 2019 | |
| Mission Pharmacal Company | $15.11 | 2019 | |
| Allergan, INC. | $13.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Finke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.